Sarepta Therapeutics
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private, Public
- Established
- 1980-01-01
- Employees
- 1.3K
- Market Cap
- $13.4B
- Website
- http://www.sarepta.com
- Introduction
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.
Safety and Efficacy Study of AVI-5126 When Used on Vein Grafts Before Use in Heart by-Pass Graft Surgery (CABG)
Phase 2
Terminated
- Conditions
- Cardiovascular DiseaseCoronary Artery Bypass
- First Posted Date
- 2007-03-23
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 600
- Registration Number
- NCT00451256
Pharmacokinetic Study in Cerebral Spinal Fluid After a Single Dose of AVI-4020
Phase 1
Completed
- Conditions
- West Nile Virus
- First Posted Date
- 2006-10-13
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 14
- Registration Number
- NCT00387283
- Locations
- 🇺🇸
NW Kinetics, Tacoma, Washington, United States
Pharmacokinetic Study of a Single Dose of AVI-4065 in Cerebral Spinal Fluid
Phase 1
Completed
- Conditions
- Encephalitis
- First Posted Date
- 2006-09-27
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 12
- Registration Number
- NCT00381433
- Locations
- 🇺🇸
NW Kinetics, Tacoma, Washington, United States
Pharmacokinetic Study of a Single Dose of AVI-4126 (RESTEN-NG®) in Cerebral Spinal Fluid
Phase 1
Completed
- Conditions
- Neoplasms
- First Posted Date
- 2006-06-22
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 6
- Registration Number
- NCT00343148
- Locations
- 🇺🇸
NW Kinetics, Tacoma, Washington, United States
Safety and Efficacy of RESTEN-MP When Used in Conjunction With a Bare Metal Stent in Coronary Arteries
Phase 2
Completed
- Conditions
- Coronary Artery DiseaseCoronary Restenosis
- First Posted Date
- 2005-11-03
- Last Posted Date
- 2007-02-08
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00248066
- Locations
- 🇩🇪
Cardiology Clinic, University Hospital of Essen, Essen, Germany
🇩🇪Coburg Hospital - Cardiology Clinic, Coburg, Germany
🇩🇪University Hospital of Heidelberg, Cardiology Clinic, Heidelberg, Germany
A Phase 1b Study Evaluating RESTEN-MP in Subjects With Focal de Novo Stenosis
Phase 1
Terminated
- Conditions
- Coronary Artery DiseaseCoronary Stent Restenosis
- First Posted Date
- 2005-10-27
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 40
- Registration Number
- NCT00244647
Study of AVI-4065 in Healthy Volunteers and Chronic Active HCV Patients
Phase 1
Terminated
- Conditions
- Hepatitis C
- First Posted Date
- 2005-09-30
- Last Posted Date
- 2008-04-10
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 80
- Registration Number
- NCT00229749
An Exploratory Study of AVI-4020 in Patients With Possible Acute Neuroinvasive West Nile Virus (WNV) Disease
Phase 1
Terminated
- Conditions
- West Nile Fever
- First Posted Date
- 2004-09-21
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Sarepta Therapeutics, Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT00091845
© Copyright 2025. All Rights Reserved by MedPath